Pharma News

Multitasking may damage your brain

  • Posted on: 29 April 2015
  • By: admin

Multitasking may hamper your performance and even damage your brain, new research has claimed. A study conducted at Stanford University found that people who are regularly bombarded with several streams of electronic information cannot pay attention, recall, or switch from one job to another as well as those who complete one task at a time.

Takeda to Settle vast majority of ACTOS (pioglitazone HCl) product liability lawsuits

  • Posted on: 29 April 2015
  • By: admin

Deerfield, Ill., U.S., April 28, and Osaka, Japan, April 29, 2015 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that they have reached an agreement expected to resolve the vast majority of ACTOS (pioglitazone HCl) product liability lawsuits pending against Takeda in the U.S. Takeda will take a $2.7 billion charge against earnings in the fourth quarter of fiscal year 2014 to cover the settlement and the costs associated with defending remaining cases and for other related litigation. The settlement will become effective if 95 percent of current litigants and claimants opt into the settlement. Once that threshold is achieved, Takeda will pay $2.37 billion into a settlement fund. However, that figure will rise to $2.4 billion if 97 percent or more of the current litigants and claimants opt to participate in the settlement.

Biocon's CRO arm Syngene seeks approval for IPO, files DRHP; offer allows Biocon to monetize its shareholding in Syngene

  • Posted on: 28 April 2015
  • By: PharmaTutor News

(Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, today announced that its Contract Research subsidiary Syngene International Ltd (“Syngene”) has filed the Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on April 22, 2015, seeking approval for an Initial Public Offering (IPO). This is an offer for sale (OFS) by Biocon of a part of its shareholding in Syngene. Biocon along with its subsidiary Biocon Research Limited (BRL) currently holds an 84.5% equity stake in Syngene.

Launch Avycaz by Actavis in US markets to treat cIAI and complicated urinary tract infections

In the United States, Actavis plc, global pharmaceutical company, has launched Avycaz (ceftazidime-avibactam) to treat adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Avycaz should be reserved for use in patients who have limited or no alternative treatment options.

Egg White Can Help Make Antibacterial Bioplastic

  • Posted on: 27 April 2015
  • By: admin

Bioplastics made from protein sources such as egg albumin and whey may have significant antibacterial properties, scientists, including those of Indian-origin, have found. The findings could eventually lead to their application in plastics used in medical applications such as wound healing dressings, sutures, catheter tubes and drug delivery. The bioplastic materials could also be used for food packaging, researchers said.

Mylan launches in India generic sofosbuvir 400 mg tablets to treat chronic hepatitis C

  • Posted on: 27 April 2015
  • By: Shalini.Sharma

Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V.,  has launched generic sofosbuvir 400 mg tablets under the brand name MyHep in India. The product is used for the treatment of chronic hepatitis C,which is a long-lasting infection with the hepatitis C virus. Chronic hepatitis C is a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.

Mauna Kea Technologies inventor of Cellvizio receives Mexican approval

  • Posted on: 25 April 2015
  • By: Shalini.Sharma

Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, has received regulatory approval from COFEPRIS (Comisión Federal Para la Protección contra Riesgos Sanitarios), the Mexican health authority, for the commercialization of Cellvizio.. Mauna Kea Technologies is now able to implement its marketing strategy with its partner, Endomédica, a company specialized in the fields of interventional endoscopy, gastroenterology, urology and surgery since 1986.

Pages